Go to the list of all blogs
published in Blogs
Jul 21, 2026
BBUS vs. SPY: Weighing Lower Fees Against Liquidity for Core U.S. Equity Exposure

BBUS vs. SPY: Weighing Lower Fees Against Liquidity for Core U.S. Equity Exposure

Key Takeaways

  • JPMorgan BetaBuilders U.S. Equity ETF (BBUS) tracks a broader index that includes large- and mid-cap U.S. equities, while SPDR S&P 500 ETF Trust (SPY) strictly follows the S&P 500 Index of large-cap companies.
  • BBUS features a significantly lower expense ratio of 0.02% compared to SPY’s 0.0945%, enhancing long-term cost efficiency for buy-and-hold investors.
  • Both ETFs exhibit highly similar top holdings and sector allocations, with heavy concentration in technology names such as NVDA, AAPL, and MSFT.
  • SPY provides unmatched liquidity and trading volume, making it preferable for active traders and institutional use despite the higher fee.
  • BBUS offers slightly broader diversification through mid-cap exposure, while maintaining a passive, market-cap-weighted approach similar to SPY.
  • In the current U.S. equity environment, structural cost advantages and comparable market exposure position both as core holdings, with choice driven by investor priorities on fees versus liquidity.

Introduction

Investors looking for core U.S. equity exposure often find themselves comparing BBUS and SPY as they target overlapping segments of the domestic market. These ETFs do not compete directly in every dimension but serve as alternatives within the large-cap blend category, allowing investors to balance cost efficiency, liquidity needs, and slight differences in market-cap coverage. In an environment of persistent technology sector influence and macroeconomic uncertainty, understanding their structural distinctions helps refine portfolio construction for both long-term allocation and tactical positioning. When I first looked at these two side by side, I also checked this using Tickeron’s AI Screener to see how they stack up against other broad equity options.

BBUS Overview

JPMorgan BetaBuilders U.S. Equity ETF (BBUS) is a passively managed fund that seeks to track the Morningstar US Target Market Exposure Index. This index provides exposure to approximately 85% of the U.S. equity market by market capitalization, encompassing large- and mid-cap companies across sectors. The ETF typically holds between 470 and 550 securities, with top positions concentrated in technology leaders such as NVDA, AAPL, MSFT, AMZN, and GOOGL. Sector allocations mirror broad U.S. market weights, featuring significant technology exposure alongside financials, healthcare, and consumer discretionary. With an expense ratio of 0.02%, the fund emphasizes cost efficiency through a straightforward, market-capitalization-weighted methodology and periodic rebalancing aligned with index changes.

SPY Overview

SPDR S&P 500 ETF Trust (SPY) is a passively managed exchange-traded fund designed to replicate the performance of the S&P 500 Index, which comprises 503 to 504 leading large-cap U.S. companies. Launched in 1993, it remains one of the most established vehicles for broad U.S. equity exposure. Top holdings closely resemble those of BBUS, led by NVDA, AAPL, MSFT, AMZN, and GOOGL, with technology representing the largest sector weight. The fund maintains a market-capitalization-weighted structure with quarterly rebalancing tied to index constituent changes. Its expense ratio stands at 0.0945%, reflecting its premium liquidity profile and institutional-grade trading characteristics that support tight bid-ask spreads and high daily volume.

Industry and Thematic Backdrop

The U.S. equity market continues to be shaped by technology sector dominance, driven by advancements in artificial intelligence, cloud computing, and semiconductor demand. Capital flows favor large-cap growth names, while interest rate expectations and corporate earnings cycles influence broader sector rotation. Regulatory developments around antitrust scrutiny and data privacy add measured risk to concentrated holdings. Macroeconomic factors, including inflation trends and geopolitical tensions, create periodic volatility that affects both large- and mid-cap segments. These dynamics underscore the importance of diversified, low-cost exposure within core U.S. equity allocations. From what I see, the ongoing AI-driven momentum makes it worth monitoring how these ETFs capture that trend over time.

Performance and Positioning Comparison

Over recent market cycles, both ETFs have delivered returns closely aligned with broad U.S. large-cap benchmarks, supported by strength in technology earnings. BBUS’s inclusion of mid-cap names has provided marginal diversification benefits during periods of mid-cap outperformance, while SPY’s pure large-cap focus has contributed to tighter tracking of flagship indices. Volatility differences remain modest, with SPY benefiting from exceptional liquidity that reduces trading costs during high-volume periods. Relative positioning favors cost-conscious investors in BBUS for extended holding periods, whereas active traders may prefer SPY for execution efficiency amid shifting interest rate expectations and sector momentum.

Using Tickeron’s AI Screener in Practice

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. I often use it to scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. One thing that stands out is how it can quickly highlight where BBUS and SPY sit relative to other broad-market options. Explore the AI Screener to discover additional opportunities aligned with your strategy.

Tickeron AI Verdict

Tickeron’s AI would currently favor JPMorgan BetaBuilders U.S. Equity ETF (BBUS) with moderate probability due to its structural cost advantage, comparable diversification profile, and similar sector momentum exposure. The lower expense ratio supports superior long-term compounding potential while maintaining alignment with prevailing large- and mid-cap trends, though SPY remains a strong alternative where liquidity is paramount.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: SPY, BBUS

SPY in upward trend: 10-day moving average crossed above 50-day moving average on August 05, 2026

The 10-day moving average for SPY crossed bullishly above the 50-day moving average on August 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on SPY as a result. In of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SPY just turned positive on August 03, 2026. Looking at past instances where SPY's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

SPY moved above its 50-day moving average on July 31, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SPY advanced for three days, in of 366 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for SPY moved out of overbought territory on August 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SPY broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SPY entered a downward trend on July 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Apple (NASDAQ:AAPL), Alphabet (NASDAQ:GOOG), Alphabet (NASDAQ:GOOGL), Microsoft Corp (NASDAQ:MSFT), Amazon.com (NASDAQ:AMZN), Broadcom Inc. (NASDAQ:AVGO), Meta Platforms (NASDAQ:META), Tesla (NASDAQ:TSLA), Eli Lilly & Co (NYSE:LLY).

Industry description

The investment seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of the S&P 500® Index. The trust seeks to achieve its investment objective by holding a portfolio of the common stocks that are included in the index (the “Portfolio”), with the weight of each stock in the Portfolio substantially corresponding to the weight of such stock in the index.

Market Cap

The average market capitalization across the State Street® SPDR® S&P 500® ETF ETF is 161.98B. The market cap for tickers in the group ranges from 5.24B to 5.31T. NVDA holds the highest valuation in this group at 5.31T. The lowest valued company is ENPH at 5.24B.

High and low price notable news

The average weekly price growth across all stocks in the State Street® SPDR® S&P 500® ETF ETF was 4%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was 12%. PAYC experienced the highest price growth at 34%, while DVA experienced the biggest fall at -24%.

Volume

The average weekly volume growth across all stocks in the State Street® SPDR® S&P 500® ETF ETF was -19%. For the same stocks of the ETF, the average monthly volume growth was -6% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 51
Price Growth Rating: 40
SMR Rating: 50
Profit Risk Rating: 59
Seasonality Score: -29 (-100 ... +100)
View a ticker or compare two or three
SPY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category LargeBlend

Profile
Details
Category
Large Blend
Address
PDR Services, 86 Trinity PlaceNew York
Phone
N/A
Web
www.spdrs.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.